Experimental glioma with high bHLH expression harbor increased replicative stress and are sensitive toward ATR inhibition.
CAGE
DDR
E47
RNA-Seq
bHLH transcription factors
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
2
11
2020
pubmed:
3
11
2020
medline:
3
11
2020
Statut:
epublish
Résumé
The overexpression of (basic)helix-loop-helix ((b)HLH) transcription factors (TFs) is frequent in malignant glioma. We investigated molecular effects upon disruption of the (b)HLH network by a dominant-negative variant of the E47 protein (dnE47). Our goal was to identify novel molecular subgroup-specific therapeutic strategies. Glioma cell lines LN229, LNZ308, and GS-2/GS-9 were lentivirally transduced. Functional characterization included immunocytochemistry, immunoblots, cytotoxic, and clonogenic survival assays in vitro, and latency until neurological symptoms in vivo. Results of cap analysis gene expression and RNA-sequencing were further validated by immunoblot, flow cytometry, and functional assays in vitro. The induction of dnE47-RFP led to cytoplasmic sequestration of (b)HLH TFs and antiglioma activity in vitro and in vivo. Downstream molecular events, ie, alterations in transcription start site usage and in the transcriptome revealed enrichment of cancer-relevant pathways, particularly of the DNA damage response (DDR) pathway. Pharmacologic validation of this result using ataxia telangiectasia and Rad3 related (ATR) inhibition led to a significantly enhanced early and late apoptotic effect compared with temozolomide alone. Gliomas overexpressing (b)HLH TFs are sensitive toward inhibition of the ATR kinase. The combination of ATR inhibition plus temozolomide or radiation therapy in this molecular subgroup are warranted.
Sections du résumé
BACKGROUND
BACKGROUND
The overexpression of (basic)helix-loop-helix ((b)HLH) transcription factors (TFs) is frequent in malignant glioma. We investigated molecular effects upon disruption of the (b)HLH network by a dominant-negative variant of the E47 protein (dnE47). Our goal was to identify novel molecular subgroup-specific therapeutic strategies.
METHODS
METHODS
Glioma cell lines LN229, LNZ308, and GS-2/GS-9 were lentivirally transduced. Functional characterization included immunocytochemistry, immunoblots, cytotoxic, and clonogenic survival assays in vitro, and latency until neurological symptoms in vivo. Results of cap analysis gene expression and RNA-sequencing were further validated by immunoblot, flow cytometry, and functional assays in vitro.
RESULTS
RESULTS
The induction of dnE47-RFP led to cytoplasmic sequestration of (b)HLH TFs and antiglioma activity in vitro and in vivo. Downstream molecular events, ie, alterations in transcription start site usage and in the transcriptome revealed enrichment of cancer-relevant pathways, particularly of the DNA damage response (DDR) pathway. Pharmacologic validation of this result using ataxia telangiectasia and Rad3 related (ATR) inhibition led to a significantly enhanced early and late apoptotic effect compared with temozolomide alone.
CONCLUSIONS
CONCLUSIONS
Gliomas overexpressing (b)HLH TFs are sensitive toward inhibition of the ATR kinase. The combination of ATR inhibition plus temozolomide or radiation therapy in this molecular subgroup are warranted.
Identifiants
pubmed: 33134924
doi: 10.1093/noajnl/vdaa115
pii: vdaa115
pmc: PMC7592426
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdaa115Informations de copyright
© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
Elife. 2018 Aug 10;7:
pubmed: 30095408
Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9976-81
pubmed: 16782810
Oncotarget. 2016 Aug 16;7(33):53074-53101
pubmed: 27447975
Nucleic Acids Res. 2015 Apr 30;43(8):e51
pubmed: 25653163
Int J Cancer. 2017 Jan 1;140(1):109-119
pubmed: 27501113
Mol Cancer Ther. 2013 Nov;12(11):2529-40
pubmed: 23960094
Cancer Res. 2018 Dec 15;78(24):6713-6716
pubmed: 30498082
Biochim Biophys Acta. 1994 Jun 21;1218(2):129-35
pubmed: 8018712
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Leuk Res. 2015 Jan;39(1):100-9
pubmed: 25499232
Mol Ther Oncolytics. 2018 Dec 31;12:147-161
pubmed: 30775418
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Nature. 2006 Dec 7;444(7120):756-60
pubmed: 17051156
Mol Cell Biol. 2014 Nov 15;34(22):4177-85
pubmed: 25202122
Oncogene. 2008 May 1;27(20):2897-909
pubmed: 18037961
Adv Ther. 2011 Apr;28(4):334-40
pubmed: 21432029
Trends Cell Biol. 1998 Feb;8(2):58-65
pubmed: 9695810
BMC Bioinformatics. 2014 Jun 12;15:182
pubmed: 24925680
ChemMedChem. 2017 Sep 21;12(18):1497-1503
pubmed: 28741867
Cancer Cell. 2011 Mar 8;19(3):359-71
pubmed: 21397859
Mol Cell Biol. 2000 Jan;20(2):429-40
pubmed: 10611221
Nat Commun. 2014 Jul 10;5:4361
pubmed: 25008978
Mol Cancer Ther. 2018 Aug;17(8):1670-1682
pubmed: 29891488
Cell. 1991 Jan 25;64(2):459-70
pubmed: 1846322
Nat Rev Cancer. 2014 Feb;14(2):77-91
pubmed: 24442143
Int J Hematol. 2017 Sep;106(3):328-334
pubmed: 28707218
Genes Dev. 2019 Jan 1;33(1-2):6-25
pubmed: 30602438
Genes Dev. 1995 Apr 15;9(8):935-44
pubmed: 7774811
Development. 2018 May 14;145(10):
pubmed: 29759978
Bioinformatics. 2009 Nov 1;25(21):2839-40
pubmed: 19737799
Neuron. 2011 Mar 10;69(5):906-17
pubmed: 21382551
PLoS One. 2014 Mar 19;9(3):e92444
pubmed: 24647355
Nat Rev Mol Cell Biol. 2012 Sep;13(9):579-90
pubmed: 22914294
Neural Dev. 2014 Oct 29;9:23
pubmed: 25352248
Lancet Oncol. 2014 Sep;15(10):1100-8
pubmed: 25163906
Methods Mol Biol. 2012;786:181-200
pubmed: 21938627
Genome Res. 2015 Dec;25(12):1812-24
pubmed: 26510915
Lancet Oncol. 2017 Oct;18(10):1373-1385
pubmed: 28844499
Cancer Sci. 2012 Jun;103(6):1028-37
pubmed: 22380883
Oncotarget. 2015 Dec 29;6(42):44289-305
pubmed: 26517239
Stem Cells. 2014 Oct;32(10):2583-95
pubmed: 24965159
Radiat Oncol. 2018 Apr 23;13(1):76
pubmed: 29685176
Cancer Res. 2018 Sep 1;78(17):5060-5071
pubmed: 29976574